Seven Novel and Stable Translocations Associated with Oncogenic Gene Expression in Malignant Melanoma  by Okamoto, Ichiro et al.
Seven Novel and Stable Translocations Associated with
Oncogenic Gene Expression in Malignant Melanoma1
Ichiro Okamoto*, Christine Pirker y, Martin Bilban z, Walter Berger y, Doris Losert§, Christine Marosi b,
Oskar A. Haas#, Klaus Wolff* and Hubert Pehamberger*
*Division of General Dermatology, Department of Dermatology, Center of Excellence and the Ludwig Boltzmann
Institut for Clinical and Experimental Oncology, Medical University of Vienna, Wa¨hringer Gu¨rtel 18-20, Vienna
A-1090, Austria; y Institute of Cancer Research, Divisions of Applied and Experimental Oncology, Medical
University of Vienna, Borschkegasse 8a, Vienna A-1090, Austria; zDepartment of Medical and Chemical
Diagnostics, Medical University of Vienna, Wa¨hringer Gu¨rtel 18-20, Vienna A-1090, Austria; §Section of
Experimental Oncology/Molecular Pharmacology, Department of Clinical Pharmacology, Medical University of
Vienna, Wa¨hringer Gu¨rtel 18-20, Vienna A-1090, Austria; bDepartment of Internal Medicine I, Division of Oncology,
Medical University of Vienna, Wa¨hringer Gu¨rtel 18-20, Vienna A-1090, Austria; #Children’s Cancer Research
Institute (CCRI), Kinderspitalgasse 6, Vienna A-1090, Austria
Abstract
Cytogenetics has not only precipitated the discovery of
several oncogenes, but has also led to the molecular
classification of numerous malignancies. The correct
identification of aberrations in many tumors has, how-
ever, been hindered by extensive tumor complexity and
the limitations of molecular cytogenetic techniques. In
this study, we have investigated five malignant mela-
noma (MM) cell lines from at least three different pas-
sagesusinghigh-resolutionR-banding and the recently
developed methods of comparative genomic hybrid-
ization and multicolor or multiplex fluorescence in situ
hybridization. We subsequently detected nine con-
sistent translocations, seven of which were novel:
dic(1;11)(p10;q14), der(9)t(3;9)(p12;p11), der(4)t(9;4;7)
(q33Dp15-q23Dq21), der(14)t(5;14) (q12;q32), der(9)
t(9;22)(p21;q11), der(19)t(19;20)(p13.3;p11), der(10)
t (2;12;7;10)(q31Dp12!pterDq11.2!q31Dq21) ,
der(19)t(10;19)(q23;q13), and der(20)t(Y;20)(q11.23;
q13.3). Furthermore, using the human HG-U133A Gene-
Chip, positive expression levels of oncogenes or
tumor-related genes located at the regions of chro-
mosomal breakpoints were identified, including AKT1,
BMI1, CDK6, CTNNB1, E2F1, GPNMB, GPRK7, KBRAS2,
LDB2, LIMK1,MAPK1,MEL,MP1,MUC18,NRCAM,PBX3,
RAB22A, RAB38, SNK, and STK4, indicating an associ-
ation between chromosomal breakpoints and altered
gene expression. Moreover, we also show that growth of
all five cell lines can be significantly reduced by down-
regulating CDK6 gene expression with small interfering
RNA (siRNA). Because themajority of these breakpoints
have been reported previously in MM, our results
support the ideaofcommonmechanisms in thisdisease.
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Introduction
Malignant melanoma (MM) is a fatal disease once metastasis
has occurred and a dramatic increase in incidence has been
recorded [1]. Despite successful identification of molecular
mechanisms in many malignancies using cytogenetic data,
MM still remains a challenging entity [2,3]. To date, a recurrent
involvement of chromosomes 1, 3, 6, 7, 9, 10, and 11 in MM
has frequently been reported, although common cytogenetic
aberrations with molecular characterization have yet to be
defined [3,4].
Only recently, molecular cytogenetics has been shown to be
effective in revealing complex cytogenetic events, even in MM
[5]. For example, using fluorescently labeled DNA probes,
fluorescence in situ hybridization (FISH) allows DNA copy
number and the chromosomal location of a specific gene locus
to be analyzed, thus revealing detailed information regarding
translocations or DNA copy number changes [6]. The informa-
tion provided by FISH is, however, limited to the precise location
of the probe, leaving the majority of genomic changes unde-
tected. In spite of this, multicolor or multiplex fluorescence in
situ hybridization (M-FISH) and comparative genomic hybrid-
ization (CGH) identify cytogenetic abnormalities throughout the
entire genome [7]. Using M-FISH, each human chromosome
can be distinguished by a distinct color combination, allowing
complex rearrangements to be identified [8]. CGH can deter-
mine the DNA copy number by hybridization of labeled tumor
DNA (test) and normal DNA (reference) to normal metaphase
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chromosomes [9]. The ratios of fluorescence intensities on
the chromosomes then reflect the copy number changes of
corresponding sequences in the tumor DNA. Both methods
do not require previous knowledge of genetic aberrations to
evaluate the extent of genetic gains or losses in the genome.
To gain the maximum benefit of whole genome analysis for
structural as well as numeric aberrations in MM cells, we
have combined M-FISH and CGH with CDD banding.
We then asked whether oncogenes located at these
consistently found breakpoints were dysregulated in cells
harboring the breakpoints. To gain the maximum benefit of
whole genome analysis for chromosomal aberrations, as
well as functional analysis on the mRNA level in MM cells,
we have combined our comprehensive cytogenetic data with
DNA microarray analysis. Strikingly, our results show that
the majority of stable breakpoints identified are associated
with increased oncogene expression levels when compared
to MM cell lines without the aberrations, suggesting a direct
relationship between chromosome aberrations and onco-
genic development.
Materials and Methods
Cell Lines
The human melanoma cell lines A375, MelJUSO, and
Skmel 28 were obtained from the ATCC (Manassas, VA),
and 518A2 and 607B cells were a kind gift from Dr. P. Schrier
(University of Leiden, Leiden, The Netherlands). All cells
were cultured in DMEM (Gibco BRL, Paisley, UK) supple-
mented with 10% FCS and a 1% antibiotic–antimycotic mix
(Gibco BRL) in a humidified 5% CO2–95% ambient air
atmosphere at 37jC.
R-banding
Cells were harvested and fixed as previously described
[10]. To obtain the most accurate information and high
resolution of banding patterns, we applied chromomycin/
distamycin/DAPI (CDD) staining [11]. This method provides
a high quality of reverse (R-) and 4V–6V-diamidino-2-
phenylindole-2HCl (DAPI) banding in a single experiment.
The karyotypes were classified using the International
System for Human Cytogenetic Nomenclature ISCN 1995
as recommended by the International Standing Committee
of Cytogenetic Nomenclature.
FISH and M-FISH
FISH was performed as described elsewhere [6]. As
probes, BAC clone RP 11-888H2 containing the CDK6 gene
and RP11-893C3 (4q21.21) was used to prove the involve-
ment of the CDK6 gene in the marker t(4;7;9) in the 518A2
cell line.
For M-FISH, metaphase spreads were prepared over-
night at room temperature and analyzed with M-FISH using
the SpectraVysion 24-color karyotyping assay according to
the manufacturer’s protocol (Vysis, Downers Grove, IL).
Metaphase images were captured with an epifluorescence
microscope (Zeiss, Go¨ttingen, Germany) equipped with a
charged-coupled device (CCD) camera (Photometrics,
Tucson, AZ) and using single-bandpass filters (Spectra-
Vysion optical filters; Vysis) corresponding to the fluoro-
phores SpectrumGold, SpectrumFRed, SpectrumAqua,
SpectrumRed, SpectrumGreen, and the fluorescent DAPI
counterstain. Further image processing and 24-color karyo-
typing were performed with the SpectraVysion Imaging
System (Vysis). At least 10 metaphase spreads from each
cell line were analyzed for M-FISH karyotyping.
CGH
Genomic DNA was isolated with the QIAamp DNA Blood
Mini Kit (Qiagen, Valencia, CA) according to the manu-
facturer’s instructions and stored at 20jC. Normal male
reference DNA was obtained from Promega (Mannheim,
Germany). Amplification by DOP polymerase chain reaction
(PCR) and labeling of DNA samples were performed essen-
tially as previously described [12], and 1–2 ml of the DOP-
PCR product was used for PCR labeling with Dig-11-dUTP
(tumor DNA) or Bio-16-dUTP (reference DNA) (Roche,
Mannheim, Germany). Labeling was carried out in 50-ml
reaction mixtures comprising 200 mM each of dATP, dCTP,
and dGTP each; 160 mM dTTP; 40 mM Dig-11-dUTP or Bio-
16-dUTP; 1% W1 detergent; 2 mM degenerate primer;
and 0.1 U/ml Super Taq DNA Polymerase in TAPS buffer
(25 mM TAPS, 50 mM KCl, 2 mM MgCl2, and 2.88 mM
b-mercaptoethanol) for 5 minutes at 95jC, 30 cycles of
1.5 minutes at 94jC, 1.5 minutes at 58jC, and 3 minutes
at 72jC, followed by a final extension at 72jC for 8 minutes.
Equal amounts of tumor DNA and reference DNA-PCR
products, along with a sufficient amount of human CotI
DNA (Roche), were hybridized in Hybridisol (QBIOgene,
Carlsbad, CA) on normal human metaphase slides (Vysis).
For probe detection, a 1:200 dilution of anti–Dig-FITC (Sig-
ma, St. Louis, MO) antibody and a 1:100 dilution of anti–
Biotin-Cy3 antibody (Sigma) were employed. After mounting
with DAPI containing antifade solution (Vector Laboratories,
Inc., Burlingame, CA), images were captured with a Leica
DMRXA fluorescence microscope (Leica, Wetzlar, Ger-
many) equipped with appropriate epifluorescence filters
and a COHU CCD camera. CGH profiles were analyzed
using Leica QFISH and the Leica QCGH software. Ten to
15metaphases per case were analyzed to create the median
ratio profile. Increases and decreases in DNA sequence
copy numbers were defined by tumor-to-reference ratios of
>1.2 and <0.8, and amplifications at ratios >1.4, respectively.
These reference values were established before the study by
CGH analysis of normal DNA samples from different sources
as a specificity control, as well as different mixtures of male
and female normal DNA and analyses of X-chromosome
material as a sensitivity control. The mean green-to-red ratio
of normal DNA was always between 0.8 and 1.2 on all
chromosomes, with the exception of chromosomes 19, 22,
and 1p32-pter [13], which were not included in the analyses.
Gene Expression Profiling
Total RNA was isolated from MM cell lines using the
Qiagen RNeasy Mini Kit (Qiagen) and subjected to DNA
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microarray analysis as described [14]. Briefly, 5 mg of total
RNA was reverse-transcribed into double-stranded cDNA
using the SuperScript Choice system (Invitrogen Corp.,
Carlsbad, CA). Biotinylated cRNA was prepared from ds
cDNA by in vitro transcription using the BioArray IVT kit
(Affymetrix, Santa Clara, CA), fragmented, and hybridized
to HG-U133A microarray chips (Affymetrix) at 45jC for
16 hours in a rotisserie oven at 60 rpm. Arrays were washed
using nonstringent buffer (6 SSPE: 0.9 M sodium chloride,
0.06M sodium phosphate, and 6mMEDTA, pH 7.4) at 25jC,
followed by a stringent buffer (100 mM MES, pH 6.7, 0.1 M
NaCl, and 0.01%Tween20) at 50jC, stainedwith streptavidin–
phycoerythrin (Molecular Probes, Eugene, OR), washed with
6 SSPE, incubated with biotinylated antistreptavidin IgG,
stained again with streptavidin–phycoerythrin, and washed
again with 6 SSPE. Arrays were scanned using the
GeneArray scanner (Affymetrix). The images or measure-
ments obtained were then transferred from the scanner to a
specialized software (GeneChip software, MAS 5.0; Affy-
metrix) to analyze the expression profile of each mRNA
species. Normalization was performed by global scaling,
with the arrays scaled to an average intensity of 500. Nor-
malized signal intensity values of genes located at the iden-
tified breakpoints in every MM cell line investigated were
compared and visualized using the GeneSpringh software
(Silicon Genetics, Redwood City, CA). Structural and func-
tional information was extracted from the NetAffx website
(http://www.affymetrix.com/analysis/index.affx), which
details and annotates probesets on Affymetrix GeneChip
microarrays. Sequence annotations include gene ontology
(GO) terms and depiction of GO graph relationships; pre-
dicted protein domains and motifs; orthologous sequences;
links to relevant pathways; and links to public databases
including UniGene, LocusLink, SWISS-PROT, and OMIM.
Quantitative Real-Time Reverse Transcriptase
PCR (RQ-PCR)
RQ-PCR was performed selectively for CDK6, LDB2,
MP1, and PBX3. Total RNA was isolated as described above
for analysis of gene expression profiling. Synthesis of cDNA
and RQ-PCR was performed using TaqMan Reverse Tran-
scription Reagents, TaqMan Universal Master Mix, and an
ABI Prism 7700 Sequence Detection system according to
the manufacturer’s instructions (Applied Biosystems, Foster
City, CA). Primers were purchased from Applied Bio-
systems. Relative gene expression was quantified using
the comparative threshold cycle method and GAPDH as an
internal standard.
Downregulation of CDK6 with siRNA
Two different siRNA molecules corresponding to exons
3 and 6 were purchased from Ambion, Inc. (Austin, TX). As
a control, we used previously published 21-mer double-
stranded siRNA molecules that are directed against firefly
luciferase (5V-CGUUAUUUAUCGGAGUUGCAG-3V). The in-
cubation of the cells with the siRNA was performed as
described previously [15]. Briefly, 5  103 cells were plated
onto 24-well plates for cell growth analysis, and 105 cells
onto six-well plates for expression analysis, transfected and
harvested after 24 hours for detecting mRNA levels with RQ-
PCR. For assessment of cell growth, cells were harvested
72 hours after siRNA treatment and counted with a Coulter
Z1 counter (Coulter, Luton, Beds., UK).
Results
R-banding and M-FISH
All five MM cell lines showed abnormal karyotypes with
near-triploid to tetraploid chromosome sets. At least six
characteristic aberrations (i.e., abnormalities found in more
than two cells per cell line) were identified in each cell line
with R-banding alone (Table 1). Together with M-FISH,
52 structural aberrations were detected also, confirming
the cytogenetic findings by R-banding. From the 52 structural
aberrations, 13 were centromeric translocations, eight of
which involved the centromeric region of chromosome 1,
engaging chromosomes 6 and 13 in two cell lines, followed
by chromosomes 5, 6, 10, 14, 19, and 20, all affecting the
individual centromeres. Other centromeric translocations
included t(4;8), t(4;21), t(7;13), t(8;14), and t(14;15). Iso-
chromosomes included chromosomes 4 and 8 in two cell
lines, followed by chromosomes 1, 7, 10, 13, 14, 15, 21, and
22. Breakpoints outside the centromeric regions found in
the majority of cells investigated (more than 50% of cells
per cell line) included the regions: 2q31, 3p12, 4p15, 4q23,
5p14, 5q12, 7p15, 7q11, 7q21, 7q31, 9p11, 9p21, 9q33, 10p12,
10q23, 11q14, 11q23, 14q32, 17q21, 19p13.1, 19p13.3,
20p11, 20q11.2, 20q13.3, 22q11, and Yq11.34. Apart from
centromeric translocations and isochromosomes, the most
consistent aberrations (i.e., detectable in almost all cells
throughout three passages) were: dic(1;11)(p10;q14),
der(9)t(3;9)(p12;p11), der(4)t(9;4;7)(q33Dp15-q23Dq21),
der(19)t(10;19)(q23;p13.1), der(14)t(5;14) (q12;q32), der(9)
t(9;22)(p21;q11), der(19)t(19;20)(p13.3;p11), and der(20)
t(20;Y)(q13.3;q11.3). Except der(19)t(10;19)(q23;p13.1) in
A375 and der(20)t(20;Y)(q13.3;q11.3) in Skmel 28, none of
the identified aberrations has been published in MM cases
previously. Additionally, another highly complex aberration
could be detected, consisting of chromosomes 2, 7, and 10
according to M-FISH (Figure 1). The small insertion between
the chromosomal materials 2 and 7 suggested that it con-
tained chromosomal material derived from chromosome 18
or 19 according to M-FISH, although it could not be con-
firmed by whole chromosome painting. Instead, after careful
revision of the raw images, the staining of the area con-
cerned suggested the involvement of chromosome 12,
which could then be confirmed by whole chromosome paint-
ing. Therefore, the retrospective banding annotation of this
marker chromosome resulted in an isochromosome: der(10)
t(2;12;7;10)(q31Dp12!pterDq11.2!q31Dq21). Each of
the aberrations was (although the affected breakpoints
were already being described in the past in other MM cell
lines) characteristic for one cell line. To confirm the accuracy
of the breakpoint annotations, we performed FISH at se-
lected locations as illustrated in Figure 1.
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Table 1. Structural Aberrations Detected by R-banding and Confirmed by M-FISH, Detected in More than 50% of the Cells in a Passage.
Chromosome 518 607 A375 JUSO Skmel
1 del(1)(p33) dic(1;11)(p10;q14) del(1)(p13) der(1;19)(q10;q10) del(1)(q21)
del(1)(q31) der(1;13)(p10; q10) der(1;6)(q10;p10) del(1)(q12)
i(1p) der(1;5)(q10;q10)
i(1q) der(11)t(1;11)(q41; q23)
der(1;6)(p10;p10) der(1;16)(p10;q10)
der(1;10)(p10;q10) der(1;20)(q10;q10)
der(1;13)(p10;q10)
der(1;14)(p10;p10)
2 del(2)(q11) – der(2;9)(p10;p10) – der(10)t(2;12;7;10)
(q31Dp12!pterDq11.2!q31Dq21)
der(17)t(2;17)
(p16;q21)
der(2;12)(p10;p10)
der(2;19)(p10;p10)
der(2)t(2;20)(q31;q11.2)
3 – del(3)(p22)x2 der(3;13)(q10; q10) der(9)t(3;9)(p12;p11) der(3)t(3;7)(q10;q33)
der(3)t(3;10)(p22; q25)
der(10)t(3;10)(p22; q25)
4 der(4;21)(q10;q10) – der(4;6)(p10;p10) – –
der(4)t(4;7)(q23;q21) der(4;8)(p10;q10)
der(4)t(9;4;7)
(q32Dp15-q23Dq21)
der(4;22)(q10;q10)
5 i(5q) der(5)t(5;7)(p14;p21) – der(5)t(5;14)(q12; q32) der(1;5)(q10;q10)
der(5;11)(p10; q10) i(5q)
6 der(1;6)(p10;p10) – der(1;6)(q10;p10) – –
der(6;8)(p10;q10) der(4;6)(p10;p10)
der(6;9)(p10;p10)
7 der(4)t(4;7)(q23;q21) der(5)t(5;7)(p14;p21) – der(7)t(7;21)(p15; q21) der(10)t(2;12;7;10)
(q31Dp12!pterDq11.2!q31Dq21)
der(4)t(9;4;7)
(q32Dp15-q23Dq21)
i(7p) der(3)t(3;7)(q10;q33)
del(7)(q31) del(7)(q31) i(7p)
der(7;13)(q10;q10) del(7)(q31)
8 – – der(4;8)(p10;q10) – der(8;14)(q10;q10)
9 der(4)t(4;7)(q23;q21) der(9)t(9;22)(p21;q11) der(2;9)(p10;p10) der(9)t(3;9)(p12;p11) –
der(4)t(9;4;7)
(q32Dp15-q23Dq21)
der(6;9)(p10;p10) der(9)t(9;13)(q10; q12)
der(22)t(9;22)(q31; q11)
10 der(1;10)(p10;q10) der(10)t(10;13)
(p12;q21)
der(19)t(10;19)
(q23;q13)
der(3)t(3;10)(p22; q25) der(10)t(2;12;7;10)
(q31Dp12!pterDq11.2!q31Dq21)
del(10)(p12) der(10)t(3;10)(p22; q25) del(10)(p12)
11 – dic(1;11)(p10;q14) del(11)(p15) – der(11)t(1;11)(q41; q23)
der(5;11)(p10;q10) der(11)t(1;11;1)(p32;q23;p32)
12 – – der(2;12)(p10;p10) – i(12q)
der(10)t(2;12;7;10)
(q31Dp12!pterDq11.2!q31Dq21)
13 der(1;13)(p10;q10) der(1;13)(p10;q10) der(3;13)(q10;q10) der(7;13)(q10;q10) –
i(13q) der(10)t(10;13)
(p12;q21)
der(13;19)(q10; q10)
14 der(1;14)(p10;p10) – – der(5)t(5;14)(q12; q32) der(8;14)(q10;q10)
i(14q) der(14;15)(q10;q10)
15 – – – t(14;15)(q10;q10) i(15q)
16 – der(16;19)(q10; q10) – idic(16)(?) der(1;16)(p10;q10)
17 der(17)t(2;17)
(p16;q21)
i(17q) – idic(17)(?) –
18 – – – – –
19 der(19)t(19;20)
(p13.3;p11)
der(16;19)(q10; q10) der(2;19)(p10;p10) der(1;19)(q10;q10) –
der(19;22)(q10; q10) der(19)t(10;19)
(q23;q13)
20 der(19)t(19;20)
(p13.3;p11)
– der(2)t(2;20)
(q31;q11.2)
– der(1;20)(q10;q10)
der(20)t(Y;20) (q11.23;q13.3)
21 der(4;21)(q10;q10) – – der(7)t(7;21)(p15; q21) –
22 – der(9)t(9;22)(p21;q11) der(4;22)(q10;q10) der(22)t(9;22)(q31; q11) –
der(19;22)(q10; q10)
X – – – – –
Y – – – – der(20)t(Y;20) (q11.23;q13.3)
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CGH
Due to the complexity of the aberrations that were
identified, we applied CGH to assess DNA copy number
changes and to obtain the most detailed cytogenetic infor-
mation (Figure 2). As previously described, regions 1p and
16p and chromosomes 19 and 22 were found to provide
false-positive results and, therefore, were not included in our
analysis. Generally, our CGH data were in good agreement
with cytogenetic findings in MM [16]. Losses were frequently
found on 2q, 4q, 6q, 8p, 9p, 10p, 10q21, 11q, chromosome
18, and 19q. Gains could be observed in regions 1q, 3q21,
5q, chromosome 7, 8q, 9q, chromosome 12, 14q, and chro-
mosomes 17 and 20. These data show nonrandom DNA
copy number changes shared by all five cell lines, charac-
teristic of MM. Moreover, CGH detected chromosomal
imbalances as a consequence of unbalanced transloca-
tions detected by R-banding and M-FISH for the following
aberrations: der(4)t(9;4;7) in 518A2 cells; dic(1;11),
der(9)t(9;22), and i(17q) in 607B cells; der(19)t(10;19) in
A375 cells; der(9)t(3;9), der(3;13), der(14)t(5;14), i(7p),
dic(17), and der(9)t(9;22) in JUSO cells; and der(11)t(1;11;1)
in Skmel28 cells.
Microarray
To study the functional consequences of the detected
aberrations at the mRNA level, global gene expression
profile of five MM cell lines was determined using the HG-
U133A GeneChip interrogating approximately 22,000 unique
sequences. As chromosomal aberrations such as transloca-
tions are known to lead to gene fusion or increased gene
expression of oncogenes, we focused our investigation on
the expression changes of oncogenes and other tumor-
associated genes or genes that are known to be activated
in tumors located at the identified breakpoints. We used
the following approach. First, we determined the number of
genes that showed elevated expression associated with a
particular chromosomal aberration in a particular cell line
when compared to cells that do not have this aberration.
Figure 1. (a) R-banding and M-FISH images of consistent aberrations (detectable in at least three passages). (b) The complex marker chromosome of Skmel 28 in
all single-color captures with DAPI, Gold, FarRed, Red, Aqua, and Green from left to the right.
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Next, we searched for oncogenes or other tumor-associated
genes within this list using the publicly available gGene
Ontology Mining Toolh (http://www.affymetrix.com/analysis/
index.affx). This software annotates Affymetrix Probe IDs
according to their biologic or molecular function; however,
manual literature search had to be added to achieve a
reliable annotation of the full dataset. As a result, positive
oncogene expression levels were found at 20 locations of
chromosomal breakpoints—13 of which, detected stably in
more than three passages, could be identified—when com-
pared to cell lines lacking the same chromosomal break-
points (Table 2). For example, in the 518A2 cell line, 7q21,
which harbors the cyclin-dependent kinase 6 gene (CDK6), a
member of the highly studied p16 pathway in MM, was
involved in a consistent translocation der(4)t(9;4;7). Com-
parison of CDK6 expression levels in all five MM cell lines
revealed a dominant expression level of CDK6 in 518A2
cells. CDK6 was also the only contributor downstream of p16
that showed the highest gene expression level in 518A2 cells
in comparison to other cell lines studied. Additionally, candi-
date genes that showed the highest mRNA expression levels
in the cell lines containing the breakpoint were: CTNNB1,
E2F1, GPNMB, GPRK7, KBRAS2, LDB2, LIMK1, MAPK1,
MEL, MP1, MUC18, NRCAM, PBX3, and RAB22A. CDK6,
LDB2, MP1, and PBX3 gene expression levels were con-
firmed with RQ-PCR. AKT1, BMI1, RAB38, SNK, and STK4
also yielded positive results. However, expression levels
were not as high when compared to other samples.
Downregulation of CDK6
CDK6, a component of the pRB pathway that operates
downstream of the one in which the melanoma susceptibility
gene p16 is involved, was expressed in all five MM cell lines.
To examine its functional role, we downregulated its expres-
sion with small interfering RNA (siRNA) against exons 3 and
6 in separate experiments to ensure specificity of the ensuing
effect. RQ-PCR analyses confirmed an up to five-fold reduc-
tion of the mRNA levels in all cell lines within 24 hours after
exposure to either siRNA. In agreement with the known
involvement of CDK6 in the G1 transition phase, this suc-
cessful suppression concurred with an up to 70% reduction
of cell growth within 72 hours (data not shown).
Discussion
Knowledge of cytogenetic changes leading to the deregu-
lation of oncogene expression is rapidly growing not only in
hematologic malignancies but also in solid tumors [4].
Although cytogenetic analysis of advanced MM is particu-
larly challenging due to the complex nature and variability of
chromosomal aberrations [3], it is still possible that stable
chromosomal changes that provide selective advantage to
cells might be important in tumorigenic evolution. Because
most of the breakpoints identified are being described in
other MM cases as well, our results might provide insights
into common mechanisms involved in MM evolution. So far,
most cytogenetic studies concerning MM have been limited
to a descriptive analysis of cytogenetic aberrations using
various methods speculating about their functional conse-
quences in terms of gene expression. Therefore, in this
study, we asked whether changes in oncogenic expression
at chromosomal breakpoints can be detected by comparing
MM cell lines harboring the mutation versus cell lines lack-
ing the breaks. The possible association of DNA copy
number changes with gene expression levels will be pre-
sented separately.
The combination of the two most recent and sophisticated
molecular cytogenetic techniques, CGH and M-FISH, with
Figure 2. Compiled CGH data. Lanes on the left indicate relative losses. Lanes on the right indicate relative gains of chromosomal material in individual cases.
From the center: 518A2, 607B, Mel-JUSO, A375, and Skmel 28.
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R-banding has shown to be very effective because each
technique provided answers to different questions. Addi-
tionally, CGH proved to be successful in detecting DNA
copy number changes caused by unbalanced translocations,
confirming the results of M-FISH and R-banding (Figure 2).
These results are of value as confirmation of the structural
aberrations detected, reflect the impact of these aberrations
on the overall DNA copy number changes as a conse-
quence, and confirm the clonality of the aberrations found.
Therefore, these data contribute valuable results to the
unique and emerging data arising from multicolor karyotyp-
ing and CGH.
We then asked whether cytogenetic aberrations had an
effect on the expression level of the genes located at the
chromosomal breakpoints. Using the global HG-U133A
gene chip, we were able to detect positive as well as
increased expression levels of oncogenes in 13 consistent
breakpoints (i.e., breakpoints detectable in more than three
passages in culture) in total 20 breakpoints identified in
more than 50% of the cells per sample, compared to other
cell lines deficient of the same breakpoints (Table 2). These
data provide valuable information in regard to potential
targets for further molecular investigation.
We found a complex translocation, for example, involv-
ing a breakpoint at 7q21 in 518A2. Microarray expression
analysis of this cell line revealed not only positive but also
the highest mRNA expression level of the cyclin-dependent
kinase gene located at 7q21, CDK6. With FISH using locus-
specific probes, we could prove the involvement of the
CDK6 gene in the translocation. Our functional analyses
Table 2. Oncogenes and Tumor-Associated Genes that Show Increased Expression Levels at Cytogenetically Identified Breakpoints.
Breaks Gene ID Gene Expression Levels Cytogenetic Reports in MM
518A2 607B A 375 Mel JUSO Skmel 28
518A2
4p15 LDB2 330 6 34 6 4 Ozisik et al., 1994; Thompson et al., 1995
4q23 MP1 823 490 710 487 621 –
7q21 CDK6 857 514 656 241 249 Pedersen et al., 1986; Cowan et al., 1988; Limon et al.,
1988; Thompson et al., 1995
9q33 PBX3 1040 352 494 884 536 Thompson et al., 1995
17q21 KBRAS2 637 477 484 361 398 Ochi et al., 1984; Gollin and Janecka, 1994; Morse et al.,
1994; Thompson et al., 1995
19p13.3 GPRK7 2293 816 1105 973 973 Parmiter et al., 1986; Morse et al., 1994; Barks et al., 1997
607B
10p12 BMI1 1094 1045 724 779 733 Reichmann et al., 1985; Bridge et al., 1991; Thompson et al.,
1995; Okamoto et al., 1999
11q14 RAB38 295 590 148 6204 2272 Thompson et al., 1995; Barks et al., 1997; Cowan et al.,
1988; Limon et al., 1988; Thompson et al., 1995;
Grammatico et al., 1998
22q11-13 MAPK1 616 2398 1593 1635 498 Barks et al., 1997
A375
19p13 MEL 1449 918 2068 1578 1641 Parmiter et al., 1986; Morse et al., 1994; Barks et al., 1997
20q11.2 STK4 284 136 251 161 106 –
JUSO
3p22 CTNNB1 2170 718 510 3933 715 Ozisik et al., 1994; Thompson et al., 1995
5q12 SNK 576 459 1256 467 225 Thompson et al., 1995; Okamoto et al., 1999
7p15 GPNMB 505 4848 665 10922 8976 –
14q32 AKT1 1225 1398 755 1044 956 Kakati et al., 1977; Pedersen et al., 1986; Grammatico et al.,
1993, 1995
Skmel 28
7q11.2 LIMK1 193 147 138 157 259 Kakati et al., 1977; Atkin et al., 1981; Cowan et al.,
1988; Dahlenfors et al., 1993; Grammatico et al.,
1993; Pedersen et al., 1986; Limon et al., 1988;
Thompson et al., 1995
7q31 NRCAM 30 253 65 104 983 Kakati et al., 1977; Pedersen et al., 1986; Limon et al.,
1988; Thompson et al., 1995
11q23 MUC18 2485 910 1529 3028 5136 Kakati et al., 1977; Pederson et al., 1986; Cowan et al.,
1988; Limon et al., 1988; Morse et al., 1994; Ozisik et al.,
1994; Thompson et al., 1995
20q11 E2F1 54 451 364 581 555 –
20q13 RAB22A 663 427 750 629 1006 Pedersen et al., 1986; Cowan et al., 1988; Grammatico et al.,
1993; Thompson et al., 1995
The signal range was calibrated for each gene individually to allow visualization of gene expression differences among the five cell lines.
The normalized signal intensity value of each individual gene is quoted.
The color bar is a qualitative indicator of signal intensity for a particular gene across the five cell lines and ranges from (no mRNA) detection result (blue) to high
level mRNA expression (red).
In the last column, reference is given to publications with melanoma cases harboring aberrations with the same breakpoint.
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with siRNA further corroborate the growth-promoting poten-
tial of CDK6 in MM. In this context, it is interesting to note
that researchers have recently reported elevated expres-
sion levels of the CDK6 locus in tumors developed in a
p19ARF-deficient mouse model [17]. Germline mutations
in genes encoding several components of the retinoblas-
toma (RB) pathway, including the RB gene itself, have been
positively correlated with a genetic predisposition to mela-
noma [18–20]. Our results are therefore not only in agree-
ment with data obtained from the p19ARF-deficient mouse
model, but show for the first time that the proliferation of
human melanoma cell lines can be suppressed with CDK6-
targeted siRNA.
Other genes, such as RAB38, MAPK1, CTNNB1,
GPNMB, NRCAM, MUC18, and E2F1, were reported to be
overexpressed in human MM [21–24], confirming their role
in the tumorigenesis. For the first time, our results show an
association between these oncogene expression and the
cytogenetically detectable breakpoints. It is interesting to
note that the cell lines, deficient of the breakpoints at the
locations of the oncogenes mentioned above, with the ex-
ception of RAB38, exhibited lower or a lack of mRNA
expression. Other oncogenes that revealed higher expres-
sion levels in cell lines without breakpoints, such as SNK at
5q12, AKT1 at 14q32, and MEL at 19p13, may indicate that
other mutations such as point mutations might be involved in
the upregulation of these genes. These may include down-
stream effectors of transcriptional regulators. Another expla-
nation could be the production of chimeric mRNA transcripts,
leading to positive mRNA detection but overall reduced
intensity. In either case, our findings support the involvement
of the oncogenes mentioned above and the idea of clonal
evolution due to these cytogenetic aberrations.
The existence of breakpoints without evident expression
of tumor-related genes as seen for 20p11 in 518A2, 5p14
and 9p21 in 607B, or 10q23 in A375 may be due to different
reasons. Other than the possibility of nonsignificant aber-
rations without any biologic role, they could still reflect
the possibility of new and unknown genes at the regions
affected. The most recent and comprehensive human
gene expression analysis chip HG-U133A encompassing
more than 22,000 genes still represents at least half of
the estimated number of genes comprising the human
genome [25,26]. Although our current knowledge of genes
is likely to be biased toward disease-related genes, as has
been demonstrated in the past, cytogenetics could still
provide important information on otherwise unknown genes
with a crucial role in tumor biology. For the marker chro-
mosome t(4;7;9), the involvement of the suggested genes
in translocations could be confirmed with FISH using BACs
containing the candidate genes (data not shown). There-
fore, the combination of molecular cytogenetic techniques
and microarray might be helpful in identifying targets for
further molecular studies.
Taken together, this approach has used M-FISH and
CGH, in combination with high-resolution R-banding, to
achieve the highest possible level of resolution in cyto-
genetics and found seven consistent marker chromosomes
in the cell lines investigated. Even though these aberrations
are new, the breakpoints have been previously reported in
several other MM cases. The distinctive gene expression
patterns of the cell lines—together with the stability of these
aberrations and, in particular, the location and high expres-
sion levels of potentially tumor-relevant genes in the vicinity
of the respective breakpoints and, last but not the least, our
functional siRNA studies—provide a compelling, albeit indi-
rect, evidence for a specific function of reciprocal rearrange-
ments in MM.
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